Replies to post #201560 on Biotech Values

[biomaven0]

>>better than ibrance?

Looks like it - the LLY drug has some preliminary single-agent efficacy:

http://www.dddmag.com/news/2016/05/cdk4-6-inhibitor-abemaciclib-most-active-against-breast-cancer-nsclc

[DewDiligence]

CHMP approves PFE’s Ibrance:

http://finance.yahoo.com/news/pfizer-receives-positive-chmp-opinion-112400615.html

Pfizer Inc. (PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that IBRANCE® (palbociclib) be granted marketing authorization in the European Union (EU) for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. The CHMP’s positive opinion is for IBRANCE to be used in combination with an aromatase inhibitor, as well as in combination with fulvestrant in women who have received prior endocrine therapy.

Rubber-stamping by the EU Commission will come in 2-3 months.